The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$165.46

Today's change-0.32 -0.19%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$165.46

Today's change-0.32 -0.19%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Reversal following new 100-day high

Valeant Pharmaceuticals International Inc closed lower Friday, dropping $0.32 or 0.19% to $165.46 after setting a new 100-day high. Over the last five days, shares have gained 3.00% and are currently 2.93% off of the 52-week high. Shares have outperformed the S&P TSX by 30.59% during the last year.

Key company metrics

  • Trailing P/E96.52×
  • P/E 1 year forward19.63×
  • Forward PEG0.73×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS$1.71
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6.25%

Based on its net profit margin of 6.25%, Valeant Pharmaceuticals International Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue2,0562,0411,8862,064
Total other revenue--------
Total revenue2,0562,0411,8862,064
Gross profit1,4951,4561,3681,332
Total cost of revenue561586518732
Total operating expense1,3721,6861,6231,876
Selling / general / administrative504516482450
Research & development59676160
Depreciation / amortization393366355204
Interest expense (income), net operating--------
Unusual expense (income)87153250351
Other operating expenses, total-2320-4379
Operating income684355263188
Interest income (expense), net non-operating-258-241-247-263
Gain (loss) on sale of assets--------
Other--------
Income before tax3771215-78
Income after tax276122-20125
Income tax, total100-125-203
Net income275126-23124
Total adjustments to net income--------
Net income before extra. items275126-23124
Minority interest-14-2-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items275126-23124
Inc. avail. to common incl. extra. items275126-23124
Diluted net income275126-23124
Dilution adjustment0000
Diluted weighted average shares341341335335
Diluted EPS excluding extraordinary itemsvalue per share0.810.37-0.070.37
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.010.670.431.08